Newsbenzinga
Novartis' $12 Billion Bet Pays Off With Encouraging Data From Rare Neuromuscular Disease Study
· Published
Article summary
Novartis reports positive Phase 1/2 del-brax data in FSHD, supporting Phase 3 development of a potential disease-modifying therapy.
An excerpt from the original article.
Comments —
Loading comments…